Life Extension Skin Care Sale

Epilepsy References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Epilepsy Foundation. Incidence and Prevalence 2010. Available at: http://www.epilepsyfoundation.org/aboutepilepsy/whatisepilepsy/statistics.cfm. Accessed January 22, 2012
  2. Oladipo OO, Ajala MO, Okubadejo N, et al. Plasma magnesium in adult Nigerian patients with epilepsy. Niger Postgrad Med J. 2003;10(4):234-7.
  3. Sinert R et al. Serum ionized magnesium and calcium levels in adult patients with seizures. Scand J Clin Lab Invest. 2007;67(3):317-26.
  4. Oliveira Ld et al. The role of magnesium sulfate in prevention of seizures induced by pentylenetetrazole in rats. Arq Neuropsiquiatr. 2011;69(2B):349-55.
  5. Slutsky I, Abumaria N et al. Enhancement of Learning and Memory by Elevating Brain Magnesium. Neuron 2010; 65(2): 165-177
  6. Rahman S. Mitochondrial disease and epilepsy. Dev Med Child Neurol. 2012 Jan 28. doi: 10.1111/j.1469-8749.2011.04214.x. [Epub ahead of print]
  7. Tawfik MK. Coenzyme Q10 enhances the anticonvulsant effect of phenytoin in pilocarpine-induced seizures in rats and ameliorates phenytoin-induced cognitive impairment and oxidative stress. Epilepsy Behav. 2011 Dec;22(4):671-7. Epub 2011 Oct 26.
  8. Stites T et al. Pyrroloquinoline quinone modulates mitochondrial quantity and function in mice. J Nutr. 2006 Feb;136(2):390-6.
  9. NINDS National Institute of Neurological Disorders and Stroke 2012. Available at: http://www.ninds.nih.gov/disorders/epilepsy/detail_epilepsy.htm. Accessed April 20, 2012.
  10. Jehi L and Najm IM. Sudden Death in Epilepsy: Impact, Mechanisms and Prevention. Cleveland Clinic Journal of Medicine 2008 March; 75(2) S66-70
  11. Nouri, S, Devinsky O, et al. Sudden Unexpected Death in Epilepsy 2004. Available at: http://www.emedicine.com/NEURO/topic659.htm. Accessed April 20, 2006.
  12. Nashef L, Hindocha N et al. Risk Factors in Sudden Death in Epilepsy (SUDEP): The Quest for Mechanisms. Epilepsia 2007; 48(5) 859-71
  13. Fukao K, Inoue Y et al. Magnetoencephalographic correlates of different types of aura in temporal lobe epilepsy. Epilepsia. 2010; 51(9): 1846-51
  14. Vincent A, Irani S et al. Potentially Pathogenic Autoantibodies Associated with Epilepsy and Encephalitis in Children and Adults. Epilepsia 2011; 52(Supp 8):8-11
  15. Bhalla D, Godet B et al. Etiologies of Epilepsy: A Comprehensive Review. Expert Reviews in Neurotherapeutics 2011. 11(6): 861-876.
  16. Halawa I, Andersson t et al. Hyponatremia and Risk of Seizures: A Retrospective Cross-Sectional Survey.Epilepsia 2011; 52(2):410-413
  17. Mortelmans LJ, Loo MV et al. Seizures and Hyponatremia After Excessive Intake of Diet Coke. European Journal of Emergency Medicine 2008; 51(15): 51
  18. Castilla-Guerrera L, Fernandez-Moreno MC et al. Electrolytes Disturbances and Seizures. Epilepsia 2006; 47(12):1990-1998
  19. Blaszczyk B. Influence of Coffee Drinking on Epilepsy Control. Journal of Clinical and Pre-Clinical Research 2007; 1(1): 098-099
  20. Kaufman KR, Sachdeo RC. Caffeinated beverages and decreased seizure control. Seizure. 2003 Oct;12(7):519–21.
  21. Bonilha L, Li LM. Heavy coffee drinking and epilepsy. Seizure. 2004;13(4):284-5.
  22. Chrościńska-Krawczyk M, Jargietto-Baszak M et al. Caffeine and the Anticonvulsant Potency of Antiepileptic Drugs: Experimental and Clinical Data. Pharmacological Reports 2011. 63:12-18
  23. Jankiewicz K, Chrościńska-Krawczyk M, Blaszczyk B, et al. [Caffeine and antiepileptic drugs: experimental and clinical data]. [Article in Polish]. Przegl Lek. 2007;64(11):965-7.
  24. Haut SR, Vouyiouklis M et al. Stress and Epilepsy: A Patient Perception Survery. Epilepsy and Behavior 2003; 4: 511-514
  25. Gilboa T. Emotional Stress-Induced Seizures: Another Reflex Epilepsy? Epilepsia 2011; 1-4
  26. Maggio N and Segal M. Stress and Corticosteroid Modulation of Seizures and Synaptic Inhibition in the Hippocampus. Experimental Neurology 2012.
  27. Frucht MM, Quigg M, et al. Distribution of seizure precipitants among epilepsy syndromes. Epilepsia. 2000 Dec;41(12):1534–9.
  28. Nakken KO, Solaas MH et al. Which Seizure-Precipitating Factors Do Patients With Epilepsy Most Frequently Report? Epilepsy and Behavior 2005; 6:85-89
  29. Waldbum S and Patel M. Mitochondrial Oxidative Stress in Temporal Epilepsy. Epilepsy Research 2010 Jan; 88(1) 23-45
  30. Pieczenik SR and Neustadt J. Mitochondrial Dysfunction and Molecular Pathways of Disease. Experimental and Molecular Pathology 2007; 83:84-92
  31. Halliwell B. Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs Aging. 2001;18(19):685–716.
  32. Liang LP et al. Mitochondrial oxidative stress and increased seizure susceptibility in Sod2(-/+) mice. Free Radic Biol Med. 2004 Mar 1;36(5):542-54.
  33. Sourris KC et al. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med. 2012 Feb 1;52(3):716-23. Epub 2011 Nov 21.
  34. Rowan AJ, Shaywitz BA, et al. Aspartame and seizure susceptibility: Results of a clinical study in reportedly sensitive individuals. Epilepsia. 1995 Mar;36(3):270–5.
  35. Camfield PR, Camfield CS, et al. Aspartame exacerbates EEG spike-wave discharge in children with generalized absence epilepsy: A double-blind controlled study. Neurology. 1992 May;42(5):1000–3.
  36. Butchko HH, Stargel WW et al. Aspartame: Review of Safety. Regulatory Toxicology and Pharmacology 2002; 35: S1-S93
  37. Shovic A et al. 'We think your son has Lennox-Gastaut syndrome'--a case study of monosodium glutamate's possible effect on a child. J Am Diet Assoc. 1997 Jul;97(7):793-4.
  38. Landrigan PJ. Health Effects of Environmental Toxins in Deficient Housing. Bulletins of the New York Academy of Medicine 1990; 66(5): 491-499
  39. Brenner PJ and Snyder RD. Late EEG Findings and Clinical Status After Organic Mercury Poisoning. Archives of Neurology 1980; 37(5): 282-284.
  40. Istoc-Bobis M and Gabor S. Psychological Dysfunction in Lead- and Mercury-Occupational Exposure. Revue Romaine de Sciences Sociales 1987; 31(2): 183-191
  41. Sanborn MD, Cole D et al. Identifying and Managing Adverse Environmental Health Effects: 4. Pesticides. Canadian Medical Association Journal 2002; 166(11): 1431-1436.
  42. Simpson WM and Schuman SH. Recognition and Management of Acute Pesticide Poisoning. American Family Physician 2002; 65(8):1599-1605
  43. Marson AG, Appleton R et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technology Assessment 2007; 11(37).
  44. Kwan P and Brodie MJ. Effectiveness of First Epileptic Drug. Epilepsia 2001; 42(10):1255-1260.
  45. Prunetti P and Perucca E. New and Forthcoming Anti-Epileptic Drugs. Current Opinion in Neurology 2011; 24(2):159-164.
  46. Kwan P and Brodie MJ: Early Identification of Refractory Epilepsy. New England Journal of Medicine 2000; 342(5):314-319
  47. Ochoa JG, Riche W, et al. Antiepileptic Drugs: An Overview 2005. Available at: http://www.emedicine.com/neuro/topic692.htm. Accessed April 20, 2006.
  48. Alarcon G, Valentin A, et al. Is it worth pursuing surgery for epilepsy in patients with normal neuroimaging? J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):474-80.
  49. Karceski S. Vagus Nerve Stimulation Therapy. UpToDate 2011.
  50. Qiabi M, Bouthiller A et al. Vagus Nerve Stimulation for Epilepsy:The Notre-Dame Hospital Experience. Canadian Journal of Neurological Science 2011; 38:902-908
  51. De Herdt V, Poon P et al. Vagus Nerve Stimulation For Refractory Status Epilepticus. European Journal of Pediatric Neurology 2007:261-269
  52. Shawhan A, Bailey C, et al. Vagus Nerve Stimulation for Refractory Epilepsy in Children: More to VNS Than Seizure Frequency Reduction. Epilepsia. 2009; 50(5):1220-1228.
  53. Milby AH, Halpern CH et al. Vagus Nerve Stimulation for Epilepsy and Depression. Neurotherapeutics 2008; 5:75-85
  54. Elliott RE, Carlson C et al. Refractory epilepsy in tuberous sclerosis: Vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav. 2009 Nov;16(3):454-60.
  55. McLachlan RS, Sadler M, et al. Quality of life after vagus nerve stimulation for intractable epilepsy: is seizure control the only contributing factor? Eur Neurol. 2003;50(1):16-9.
  56. Pereira EA, Green AL et al. Refractory Epilepsy and Deep Brain Stimulation. Journal of Clinical Neuroscience 2012; 19: 27-33
  57. Lega BC, Halpern CH et al. Deep brain stimulation in the treatment of refractory epilepsy: Update on current data and future directions. Neurobiology of Disease 38 (2010) 354–360
  58. Wakerley B, Schweder Pet al. Possible seizure suppression via deep brain stimulation of the thalamic ventralis oralis posterior nucleus Case Reports / Journal of Clinical Neuroscience 18 (2011) 972–973.
  59. Janszky J et al. [Role of deep brain stimulation in epilepsy]. Ideggyogy Sz. 2011 Sep 30;64(9-10):317-20.
  60. Chen R, Classen J et al. Depression of Motor Cortex Excitability by Low-Frequency Transcranial Magnetic Stimulation. Neurology 1997; 48(5): 1398-1403.
  61. Sun W, Fu W et al. Low-Frequency Repetitive Transcranial Magnetic Stimulation for the Treatment of Refractory Partial Epilepsy. Clinical EEG Neuroscience 2011. 42(1) 40-44
  62. Bae EH, Schrader LM et al. Safety and Tolerability of Repetitive Transcranial Magnetic Stimulation in Patients with Epilepsy: A Review of the Literature. Epilepsy and Behavior 2007; 10(4) 521-528.
  63. Rotenberg A. Prospects for Clinical Applications of Transcranial Magnetic Stimulation and Real-Time EEG in Epilepsy. Brain Topography 2010; 22(4): 257-266.
  64. Lysing-Williamson KA: Spotlight on Levetiracetam in Epilepsy. CNS Drugs 2011; 25 (10): 901-905
  65. Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem. 1999 Jul;42(14):2582-7.
  66. Ambrósio AF, Silva AP, Araújo I, et al. Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. Eur J Pharmacol. 2000 Oct;406(2):191-201.
  67. Fattore C, Perucca E. Novel medications for epilepsy. Drugs. 2011 Nov;71(16):2151-78.
  68. Duncan GE, Kohn H. The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res. 2005 Oct-Nov;67(1-2):81–7.
  69. Errington AC, Stohr T, Heers C, et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008; 73: 157-69
  70. Curia G, Biagini G, Perucca E, et al. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009; 23: 555-68
  71. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 2007;73(1):1-52.
  72. Maa EH, Kahle KT, Walcott BP, et al. Diuretics and epilepsy: will the past and present meet? Epilepsia. 2011 Sep;52(9):1559-69.
  73. Ahmad S, Clarke L, Hewett AJ, Richens A. (1976) Controlled trial of furosemide as an antiepileptic drug in focal epilepsy. Br J Clin Pharmacol 3:621–625.
  74. El-Khayat HA, Soliman NA. Reproductive Hormonal Changes and Catamenial Pattern in Adolescent Females with Epilepsy. Epilepsia 2008; 49(9):1619-1626
  75. Finocchi C and Ferrari M. Female Reproductive Steroids and Neuronal Excitability. Neurological Science 2011; 32:S31-S35
  76. Murialdo G, Magri F et al. Seizure Frequency and Sex Steroids in Women With Partial Epilepsy on Antiepileptic Therapy. Epilepsia 2009; 50(8):1920-1926.
  77. Erel T and Guralp O. Epilepsy and Menopause. Archives of Gynecology and Obstetrics 2011; 284:749-755
  78. Stevens SJ and Harden CL. Hormonal Therapy for Epilepsy. Current Neurological and Neuroscience Reports 2011; 11:435-442
  79. Veliskova J, Jesus GD et al. Females, Their Estrogens and Seizures. Epilepsia 2010; 51(3):141-144
  80. Frye CA, Ryan A et al. Antiseizure effects of 3a-androstanediol and/or 17b-estradiol may involve actionsat estrogen receptor b. Epilepsy and Behavior 2009; 16:418-422
  81. Reddy DS and Jian K. The Testosterone-Derived Neurosteroid Androstanediol Is a Positive Allosteric Modulator of GABAA Receptors. The Journal of Pharmacology and Experimental Therapeutics. 2010 Sep;334:1031–1041
  82. Tan M, Tan U. Effects of testosterone and clomiphene on spectral EEG and visual evoked response in a young man with posttraumatic epilepsy. Int J Neurosci. 2001 Jan;106(1-2):87-94.
  83. Kelley SA and Hartman AL.Metabolic Treatments for Intractable Epilepsy. Seminars in Pediatric Neurology 2011; 18:179-185
  84. Francois LL, Manel V, et al. [Ketogenic regime as anti-epileptic treatment: Its use in 29 epileptic children]. Arch Pediatr. 2003 Apr;10(4):300–6. French.
  85. Stafstrom CE, Bough KJ. The ketogenic diet for the treatment of epilepsy: a challenge for nutritional neuroscientists. Nutr Neurosci. 2003 Apr;6(2):67-79.
  86. Sheth RD, Stafstrom CE. Intractable pediatric epilepsy: vagal nerve stimulation and the ketogenic diet. Neurol Clin. 2002 Nov;20(4):1183-94.
  87. Mady MA, Kossoff EH, et al. The ketogenic diet: adolescents can do it, too. Epilepsia. 2003 Jun;44(6):847-51.
  88. Kosoff EH, Zupec-Kania BA et al. Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group. Epilepsia, 50(2):304–317, 2009
  89. Bough KJ and Rho JM. Anticonvulsant Mechanisms of the Ketogenic Diet. Epilepsia 2007; 48(1):43-58
  90. Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy. Pediatrics. 2000 Apr;105(4):E46.
  91. Henderson CB, Filloux FM et al. Efficacy of the Ketogenic Diet as a Treatment Option for Epilepsy: A Meta-Analysis. Journal of Child Neurology 2006;21:193
  92. Neal EG, Chaffe H et al. The Ketogenic Diet for the Control of Childhood Epilepsy: A Randomised Control Trial.Lancet Neurology 2008;7:500-506
  93. Mady MA, Kossoff EH, McGregor AL, et al. The ketogenic diet: adolescents can do it, too. Epilepsia. 2003 Jun;44(6):847-51.
  94. Mosek A, Natour H et al. Ketogenic Diet in Adults with Refractory Epilepsy: A Prospective Pilot Study. Seizure 2009; 18:30-33
  95. Klein P, Janousek J et al. Ketogenic Diet Treatment in Adults with Refractory Epilepsy. Epilepsy and Behavior 2010; 19:575-579
  96. Payne NE, Cross JH et al. The Ketogenic Diet and Related Diets in Adolescents and Adults---A Review. Epilepsia 2011; 52(11):1941-1948.
  97. Kang HC, Chung DE, Kim DW, Kim HD. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia. 2004;45(9):1116.
  98. Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet in the treatment of epilepsy. Dev Med Child Neurol. 2006 Dec;48(12):978-81.
  99. Bergqvist AG, Schall JI, Stallings VA. Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia. 2007;48(1):66.
  100. McNally MA, Pyzik PL, Rubenstein JE, Hamdy RF, Kossoff EH. Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet. Pediatrics. 2009;124(2):e300.
  101. Bank IM, Shemie SD, Rosenblatt B, Bernard C, Mackie AS. Sudden cardiac death in association with the ketogenic diet. Pediatr Neurol. 2008;39(6):429.
  102. Wolf, P. Epileptic Seizures and Syndromes: With Some of their Theoretical Inplications. John Libbey Eurotext 1994.
  103. Elsas SM, Gregory WL et al. Aura interruption: The Andrews/Reiter behavioral intervention may reduce seizures and improve quality of life — A pilot trial. Epilepsy and Behavior 2011; 22:765-772.
  104. Jaseja H. Purpose of REM sleep: Endogenous anti-epileptogenesis in man—a hypothesis. Med Hypotheses. 2004;62(4):546–8.
  105. Swinehart R. Two cases support the benefits of transcendental meditation in epilepsy. Med Hypotheses. 2008;70(5):1070. Epub 2008 Jan 14.
  106. Arida RM, Scorza FA et al. The Potential Role of Physical Exercise in the Treatment of Epilepsy. Epile[psy and Behavior 2010; 17:432-435
  107. Arida RM, Scorza FA et al. Physical Exercise in Epilepsy: What Kind of Stressor Is It? Epilepsy and behavior 2009. 16:381-387
  108. Tozzo CA, Elfner LF, et al. EEG biofeedback and relaxation training in the control of epileptic seizures. Int J Psychophysiol. 1988 Aug;6(3):185-94.
  109. Andrews DJ, Schonfeld WH. Predictive factors for controlling seizures using a behavioural approach. Seizure. 1992 Jun;1(2):111-6.
  110. Ramaratnam S, Baker GA, Goldstein L. Psychological treatments for epilepsy. Cochrane Database Syst Rev. 2001;(4):CD002029.
  111. Tan G, Thornby J et al. Meta-Analysis of EEG Biofeedback in Treating Epilepsy. Clinical EEG and Neuroscience 2009; 40(3)
  112. Nagai Y. Biofeedback For Epilepsy. Current Neurological and Neuroscience Reports 2011. 11:443-450.
  113. Lundgren T, Dahl J, Yardi N, et al. Acceptance and Commitment Therapy and yoga for drug-refractory epilepsy: a randomized controlled trial. Epilepsy Bahav. 2008 Jul;13(1):102-8.
  114. Khan N, Ahmad N et al. Epilepsy Control by Prayer Type Yoga Exercise. Computer Research and Development 2010: 391-395
  115. Cheuk DK and Wong V. Acupuncture for Epilepsy. CochraneDatabase of Systematic Reviews 2008, Issue 4.
  116. Ramaratnam S, Baker GA, Goldstein LH. Psychological treatments for epilepsy. Cochrane Database Syst Rev. 2008 Jul;(3):CD002029. Update of Cochrane Database Syst Rev. 2004;(4):CD002029.
  117. Menon B and Harinarayan CV. The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism—A longitudinal study. Seizure 2010;19:153-158
  118. Shellhaas RA and Joshi SM. Vitamin D and Bone Health Among Children with Epilepsy. Pediatric Neurology 2010; 42:385-393.
  119. Pack AM and Morell MJ. Epilepsy and Bone Health in Adults. Epilepsy and Behavior 2004; 5:S024-S029.
  120. Valsamis HA, Arora SK et al. Antiepileptic Drugs and Bone Metabolism. Nutrition and Metabolism 2006;3(36)
  121. Mintzer S, Boppana P, et al. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia. 2006 Mar;47(3):510–5.
  122. Fong CY, Mallick AA, Burren CP, et al. Evaluation and management of bone health in children with epilepsy on long-term antiepileptic drugs: United Kingdom survey of paediatric neurologists. European Journal of Pediatric Neurology 2011; 15(5):417-423
  123. Sener U, Zorlu Y et al. Effects of common anti-epileptic drugmonotherapy on serum levels of homocysteine, Vitamin B12, folic acid and Vitamin B6. Seizure 2006;15:79-85
  124. Linnebank M, Moskau S et al. ;Antiepileptic Drugs Interfere with Folate and Vitamin B12 Serum Levels. Annals of Neurology 2011; 69:352-359
  125. Kurul S, Unalp A et al. Homocysteine Levels in Epileptic Children Receiving Antiepileptic Drugs. Journal of Child Neurology 2007; 22(12): 1389-1392.
  126. Apeland T, Mansoor MA et al. Antiepileptic Drugs as Independent Predictors of Plasma Total Homocysteine Levels. Epilepsy Research 2001; 47:27-36
  127. Diaz-Arrastia R. Homocysteine and Neurologic Disease. Archives of Neurology 2000;57:1422-1427
  128. Morrell MJ. Folic Acid and Epilepsy. Epilepsy Curr. 2002 Mar;2(2):31-34.
  129. Djukic A. Folate-Responsive Neurologic Diseases. Pediatric Neurology 2007; 37:387-397
  130. Asadi-Pooya AA. Risk Factors for Carbemazepine-Induced Leukopenia in Children and Adolescents. Journal of Pediatric Neurology 2005. 3:233-235.
  131. Asadi-Pooya AA, Minzer S, Sperling M. Nutritional supplements, foods, and epilepsy: Is there a relationship? Epilepsia. 2008;49(11):1819-27.
  132. Gaby AR. Natural Approaches to Epilepsy. Alternative Medicine Review. 2007; 12(1):9-24.
  133. Tamura T, Aiso K, Johnston KE, et al. Homocysteine,folate, vitamin B-12 and vitamin B-6 in patientsreceiving antiepileptic drug monotherapy. Epilepsy Res 2000;40:7-15.
  134. Jiao FY, Gao DY, Takuma Y, et al. Randomized, controlled trial of high-dose intravenous pyridoxine in the treatment of recurrent seizures in children. Pediatr Neurol 1997;17:54-57.
  135. Wang HS, Kuo MF, Chou ML, et al. Pyridoxalphosphate is better than pyridoxine for controlling idiopathic intractable epilepsy. Arch Dis Child 2005;90:512-515.
  136. Tamai H, Wakamiya E, Mino M, Iwakoshi M. Alphatocopherol and fatty acid levels in red blood cells in patients treated with antiepileptic drugs. J Nutr Sci Vitaminol (Tokyo) 1988;34:627-631.
  137. Zaidi SM, Banu N. Antioxidant potential of vitamins A, E and C in modulating oxidative stress in rat brain. Clin Chim Acta. 2004 Feb;340(1-2):229–33.
  138. Savaskan NE, Brauer AU, et al. Selenium deficiency increases susceptibility to glutamate-induced excitotoxicity. FASEB J. 2003 Jan;17(1):112–4.
  139. Yamamoto N, Kabuto H, et al. Alpha-tocopheryl-L-ascorbate-2-O-phosphate diester, a hydroxyl radical scavenger, prevents the occurrence of epileptic foci in a rat model of post-traumatic epilepsy. Pathophysiology. 2002 Jun;8(3):205–14.
  140. Ogunmekan AO. Vitamin E deficiency and seizures in animals and man. Can J Neurol Sci 1979;6:43-45.
  141. Ogunmekan AO, Hwang PA. A randomized, double-blind, placebo-controlled, clinical trial of D-alpha-tocopheryl acetate (vitamin E), as add-on therapy, for epilepsy in children. Epilepsia. 1989 Jan;30(1):84–9.
  142. Ogunmekan AO. Plasma vitamin E (alpha tocopherol) levels in normal children and in epileptic children with and without anticonvulsant drug therapy. Trop Georgr Med. 1985;37(2):175-7.
  143. Levy SL, Burnham WM et al. An Evaluation of the Anticonvulsant Effects of Vitamin E. Epilepsy Research 1990; 6:12-17.
  144. Levy SL et al. The anticonvulsant effects of vitamin E: a further evaluation. Can J Neurol Sci. 1992 May;19(2):201-3.
  145. Higashi A, Tamari H et al. Serum Vitamin E Concentration in Patients With Severe Multiple Handicaps Treated with Anticonvulsants. Pediatric Pharmacology 1980; 1:129-134.
  146. Oladipo OO et al. Plasma magnesium and calcium levels in children with epilepsy in lagos. Niger Postgrad Med J. 2007 Mar;14(1):26-9.
  147. Nuytten D, Van Hees J, Meulemans A, Carton H. Magnesium deficiency as a cause of acute intractable seizures. J Neurol 1991;238:262-264.
  148. Borges LF, Gucer G. Effect of magnesium on epileptic foci. Epilepsia 1978;19:81-91.
  149. Touyz RM. Magnesium supplementation as an adjuvant to synthetic calcium channel antagonists in the treatment of hypertension. Med Hypotheses. 1991 Oct;36(2):140-1.
  150. Gupta SK et al. Serum magnesium levels in idiopathic epilepsy. J Assoc Physicians India. 1994 Jun;42(6):456-7.
  151. Bhattacharjee N et al. A randomised comparative study between low-dose intravenous magnesium sulphate and standard intramuscular regimen for treatment of eclampsia. J Obstet Gynaecol. 2011 May;31(4):298-303.
  152. Slutsky I, Abumaria N, Wu J, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010 Jan;65(2):165-77.
  153. Abumaria N, Yin B et al. Effects of Elevation of Brain Magnesium on Fear Conditioning, Fear Extinction, and Synaptic Plasticity in the Infralimbic Prefrontal Cortex and Lateral Amygdala. Journal of Neuroscience 2011; 31(42): 14871-14881.
  154. Abumaria N, Yin B et al. Effects of Elevation of Brain Magnesium on Fear Conditioning, Fear Extinction, and Synaptic Plasticity in the Infralimbic Prefrontal Cortex and Lateral Amygdala. Journal of Neuroscience 2011; 31(42): 14871-14881.
  155. Gaby AR. Natural Approaches to Epilepsy. Alternative Medicine Review. 2007; 12(1):9-24
  156. Banach M, Gurdziel E et al. Melatonin in Experimental Seizures and Epilepsy. Pharmacological Reports 2011; 63:1-11
  157. Lima E, Cabral FR et al.Melatonin Administration After Pilocarpine-Induced Status Epilepticus: A New Way to Prevent or Attenuate Post-Lesion Epilepsy? Epilepsy and Behavior 2011; 20:607-612
  158. Costa-Latufo LV, Fonteles MM et al. Attenuating Effects of Melatonin on Pilocarpine-Induced Seizures in Rats. Comparative Biochemistry and Physiology 2002; 131:521-529
  159. Fauteck JD, Schmidt H et al. Melatonin In Epilepsy: First Results of Replacement Therapy and First Clinical Results. Biological Signals Receptors 1999; 8:105-110
  160. Blondeau N, Widmann C, et al. Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neuroscience. 2002;109(2):231–41.
  161. Taha AY, Burnham WM et al. Polyunsaturated Fatty Acids and Epilepsy. Epilepsia 2010; 51(8):1348-1358
  162. Xu X, Erichsen D et al. Polyunsaturated fatty acids and cerebrospinal fluid from children on the ketogenic diet open a voltage-gated K channel: A putative mechanism of antiseizure action. Epilepsy Research 2008;80(1):57-66.
  163. Auvin S. Fatty Acid Oxidation and Epilepsy. Epilepsy Research 2011
  164. Yuen AW, Sander JW, et al. Omega-3 fatty acid supplementation in patients with chronic epilepsy: A randomized trial. Epilepsy Behav. 2005 Sep;7(2):253–8.
  165. Bromfeld E, Dworetzky et al. A Randomized Control Trial of Polyunsaturated Fatty Acids For Refractory Epilepsy. Epilepsy and Behavior 2008; 12:187-190
  166. ClinicalTrials.gov. Double Blind Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures. Available at: http://clinicaltrials.gov/ct2/show/NCT00871377. Accessed January 22, 2012.
  167. Jyoti A, Sethi P, Sharma D. Bacopa monniera prevents from aluminum neurotoxicity in the cerebral cortex of rat brain. J Ethnopharmacol. 2007 Apr;111(1):56-62.
  168. Hosamani R et al. Neuroprotective efficacy of Bacopa monnieri against rotenone induced oxidative stress and neurotoxicity in Drosophila melanogaster. Neurotoxicology. 2009 Nov;30(6):977-85. Epub 2009 Sep 8.
  169. Kanthasamy K et al. Neuroprotective effect of resveratrol against methamphetamine-induced dopaminergic apoptotic cell death in a cell culture model of neurotoxicity. Curr Neuropharmacol. 2011 Mar;9(1):49-53.
  170. Chung IM et al. Neuroprotective effects of resveratrol derivatives from the roots of Vitis thunbergii var. sinuate against glutamate-induced neurotoxicity in primary cultured rat cortical cells. Hum Exp Toxicol. 2011 Sep;30(9):1404-8. Epub 2010 Nov 17.
  171. Shetty AK. Promise of resveratrol for easing status epilepticus and epilepsy. Pharmacol Ther. 2011 Sep;131(3):269-86. Epub 2011 Apr 28. Review.
  172. Wu Z et al. Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats. Neurochem Res. 2009 Aug;34(8):1393-400. Epub 2009 Feb 14.
  173. Pandey R et al. Baccoside A suppresses epileptic-like seizure/convulsion in Caenorhabditis elegans. Seizure. 2010 Sep;19(7):439-42. Epub 2010 Jul 3.
  174. Mathew J et al. Behavioral deficit and decreased GABA receptor functional regulation in the cerebellum of epileptic rats: effect of Bacopa monnieri and bacoside A. Epilepsy Behav. 2010 Apr;17(4):441-7. Epub 2010 Feb 11.
  175. Krishnakumar A et al. Upregulation of 5-HT2C receptors in hippocampus of pilocarpine-induced epileptic rats: antagonism by Bacopa monnieri. Epilepsy Behav. 2009 Oct;16(2):225-30. Epub 2009 Aug 22.
  176. Wallace MJ, Blair RE, et al. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003 Oct;307(1):129-37.
  177. Katona I and Freund TF. Endocannabinoid Signaling as a Synaptic Circuit Breaker in Neurological Disease. Nature Medicine 2008; 14(9).
  178. Hoffman ME and Frazier CJ. Marijuana, Endocannabinoids, and Epilepsy: Potential and Challenges for Improved Therapeutic Intervention. Experimental Neurology 2011
  179. Hill AJ, Williams CM et al. Phytocannabinoids as Novel Therapeuric Agents in CNS Disorders. Pharmacology and Therapeutics 2012; 133:79-97.
  180. Cunha JM, Carlini EA et al. Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients. Pharmacology 1980; 21(3):175-185.
  181. Ng SK, Brust JC et al. Illicit Drug Use and the Risk of New-Onset Seizures. American Journal of Epidemiology 1990; 132(1):47-57.
  182. Gross DW, Hamm J, et al. Marijuana use and epilepsy: Prevalence in patients of a tertiary care epilepsy center. Neurology. 2004 Jun 8;62(11):2095–7.
  183. Gloss D, Vickrey B. Cannabinoids for epilepsy (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 8.